Floatz logo

lm103

Solid Tumor

Suzhou BlueHorse Therapeutics Co., Ltd.Early Phase 1Active
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
59/ 100

Competitive context

927 Active assets in the Solid Tumor cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

lm103 is also rated in:

Cervical CarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
MelanomaDormant
C
Indicative ·
37 / 100
View asset →
Non Small Cell Lung CancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →